RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets pancreatic cancer before surgery
Disease control Not yet recruitingThis early-stage trial tests a drug called samuraciclib in 15 people with localized pancreatic cancer that can be surgically removed. Participants will take the drug for about two weeks before their planned surgery. Researchers will check safety and look for changes in tumor cell…
Matched conditions: RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to outsmart pancreatic cancer before surgery
Disease control Not yet recruitingThis early-phase trial will test whether adding the study drug NP137 to standard chemotherapy (FOLFIRINOX) can change the behavior of pancreatic cancer cells before and after surgery. About 25 people with resectable pancreatic cancer will receive the combination, and researchers …
Matched conditions: RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Aram Hezel • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC